Monday, February 29, 2016 8:19:44 AM
News
RespireRx Pharmaceuticals Inc. Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase 2A Clinical Trial by March 31, 2016
Glen Rock, N.J., Feb. 29, 2016/Globe Newswire – RespireRx Pharmaceuticals Inc. (OTC QB: RSPI as of January 11, 2016; previously OTC QB: CORX) (“RespireRx” or the “Company”), a leader in developing medicines for respiratory disorders, particularly sleep apnea and drug-induced respiratory depression, announced today that it has received notice that the U.S. Food and Drug Administration (the "FDA") has removed the clinical hold on the Company's Investigational New Drug application for CX1739, allowing the initiation of clinical trials. The Company intends to begin a Phase 2A clinical trial by March 31, 2016 to confirm the ability of CX1739, the Company’s proprietary lead ampakine, to antagonize the respiratory depressant effects of fentanyl, a potent opioid, without altering its analgesic properties. This pharmacological property previously had been reported for CX717, a predecessor ampakine.
Dr. James S. Manuso, President and Chief Executive Officer of RespireRx, commented, “We are extremely pleased to announce the advancement of the clinical and regulatory development of CX1739 for opioid-induced respiratory depression, the first of several indications involving respiratory disorders. The FDA clearance of our Phase 2A clinical trial of CX1739 provides further validation of RespireRx’s worldwide leadership role in the research and development of next-generation ampakine medicines. The RespireRx management team is committed to further developing its ampakine portfolio of medicines for a variety of indications where central nervous system-mediated breathing disorders may play a significant role, as is the case in Central Sleep Apnea, Pompé Disease and spinal cord injury. We look forward to reporting on our progress in the months and years ahead.”
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 08:05:55 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 08/14/2023 08:15:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2023 12:52:24 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM